InflaRx (IFRX) Net Cash Flow Growth (3y) (2019 - 2026)
InflaRx (IFRX) Net Cash Flow Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -35.85% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 106.37% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 67.39% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -70.95% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 52.78% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.55% |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.13% |
| Dec 31, 2025 | 123.71% |
| Sep 30, 2025 | -85.16% |
| Jun 30, 2025 | -9.21% |
| Mar 31, 2025 | 28.52% |
| Dec 31, 2024 | 42.47% |
| Sep 30, 2024 | 173.37% |
| Jun 30, 2024 | 14.14% |
| Mar 31, 2024 | -40.13% |
| Dec 31, 2023 | 25.35% |
| Sep 30, 2023 | -41.26% |
| Jun 30, 2023 | 3.65% |
| Mar 31, 2023 | -0.89% |
| Dec 31, 2022 | -29.27% |
| Sep 30, 2022 | 27.15% |
| Jun 30, 2022 | -158.37% |
| Mar 31, 2022 | 52.06% |
| Dec 31, 2021 | -405.96% |
| Sep 30, 2021 | 84.22% |
| Jun 30, 2021 | -32.01% |